Vitrolife Q1 update: Entering 2024 with low growth - Redeye

Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024. The combined effect from insourcing (PGT-A), ERA and EmbryoMap switching will likely contribute to a considerable headwind in Q2 (ERA could improve). Our updated view is a base case valuation of SEK 220 (245), a Bull Case of SEK 365(400), and a Bear Case of SEK 95 (100).

Länk till analysen i sin helhet: https://www.redeye.se/research/996552/vitrolife-q1-update-entering-2024-with-low-growth?utm_source=finwire&utm_medium=RSS